Novavax, Inc. (NVAX) Balance Sheet

The persistent negative equity suggests that the company has effectively exhausted its retained earnings, leaving the balance sheet reliant on external financing or licensing inflows to maintain operations. Investors should monitor whether this trajectory can be reversed through the Sanofi partnership or if the structural deficit will necessitate further dilutive capital raises.

While the current ratio suggests a temporary reprieve from immediate insolvency, the reliance on non-recurring milestones makes the liquidity position highly sensitive to operational delays. The volatility in cash reserves, which dropped from $680.2M in 2024Q2 to $228.4M in 2026Q1, indicates that the company lacks a consistent internal buffer against unexpected R&D or regulatory setbacks.

This reduction in physical assets may indicate an attempt to lower fixed costs, but it also limits the company's future operational flexibility should demand for its proprietary technology surge. The remaining asset base is heavily weighted toward intangible factors, which warrants caution regarding potential future impairment risks if the commercial pipeline fails to gain traction.